Bibliography
- Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44
- Lehto S, Rönnemaa T, Haffner SM, et al. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997;46:1354-9
- National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): final report. Circulation 2002;106:3143-421
- American Diabetes Association. Standards of Medical Care in Diabetes-2009. Diabetes Care 2009;32(Suppl 1):S29-S31
- Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002;106:2526-9
- Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American diabetes association and the American college of cardiology foundation. J Am Coll Cardiol 2008;51:1512-24
- Bittner V, Hardison R, Kelsey SF, et al. Bypass Angioplasty Revascularization Investigation. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 2002;106:2537-42
- McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008;372:224-33
- Kastelein JJ, van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008;17:3002-9
- Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006;29:1220-6
- Ballantyne CM, Andrews TC, Hsia JA, et al. Atorvastatin Comparative Cholesterol Efficacy and Safety Study. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001;88:265-9
- Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
- Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1497-504
- Borggreve SE, De Vries R, Dullaart RPF. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin: cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003;33:1051-69
- Guérin M, Le Goff W, Lassel TS, et al. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001;21:282-8
- The Diabetes Atorvastatin Lipid Intervention (DALI) study group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. Diabetes Care 2001;24:1335-41
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
- Steinmetz J, Tarallo P, Fournier B, et al. Reference limits of apolipoprotein A-I and apolipoprotein B using an IFCC standardized immunonephelometric method. Eur J Clin Chem Clin Biochem 1995;33:337-42
- Marcovina SM, Albers JJ, Kennedy H, et al. International federation of clinical chemistry standardization project for the measurements of Apolipoprotein A-1 and B. IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem 1994;40:586-92
- Van Venrooij FV, Stolk RP, Banga JD, et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 2003;26:1216-23
- Dullaart RPF, De Vries R, Scheek L, et al. Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest 2004;27:205-15
- Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol 2008;52:626-32
- Leroux G, Lemieux I, Lamarche B, et al. Influence of triglyceride concentration on the relationship between lipoprotein cholesterol and apolipoprotein B and A-I levels. Metabolism 2000;49:53-61
- Rubiés-Prat J, Reverter JL, Sentí M, et al. Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care 1993;16:1081-6
- Hirany S, Li D, Jialal I. A more valid measurement of low-density lipoprotein cholesterol in diabetic patients. Am J Med 1997;102:48-53
- De Vries R, Perton FG, Dallinga-Thie GM, et al. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes 2005;4:3554-9
- Dullaart RPF, Dallinga-Thie GM, Wolffenbuttel BH, Van Tol A. CETP inhibition in cardiovascular risk management: a critical appraisal. Eur J Clin Invest 2007;37:90-8
- Dallinga-Thie GM, Dullaart RPF, Van Tol A. Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins. Curr Opin Lipidol 2007;18:251-7
- De Vries R, Kerstens MN, Sluiter WJ, et al. Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia 2005;48:1105-13
- Chouinard RA Jr, Luo Y, Osborne TF, et al. Sterol regulatory element binding protein-1 activates the cholesteryl ester transfer protein gene in vivo but is not required for sterol up-regulation of gene expression. J Biol Chem 1998;273:22409-14